|
Patent landscape, scope, and claims: |
Scope and Claim-By-Claim Patent Landscape Analysis for US Patent 10,414,831 (Hydrogenated Dextran Oligosaccharides + Ferric Oxyhydroxide Iron Oligosaccharides)
US Patent 10,414,831 is a composition-of-matter and formulation patent centered on a tightly specified class of hydrogenated dextran oligosaccharides (molecular-weight distribution, low dimer content) that form stable iron oligosaccharide complexes with ferric oxyhydroxide. Claim scope is driven primarily by (1) hydrogenated dextran MW distribution cutoffs, (2) dimer/monomer saccharide impurity constraints, (3) “apparent molecular weight” (MP) of the final iron complex (including narrow sub-ranges), and (4) formulation elements (sterilization by autoclaving, Fe loading, and optional citrate). Practical competitive risk is therefore highest for products that land in the same MW/impurity window and target the same iron complex MP band, including the narrow 130,000–160,000 Da window. Broader “steel thread” workarounds exist for competitors by moving either (i) the hydrogenated dextran MW distribution outside the defined percentiles, or (ii) the final iron complex MP outside the claimed bands, even if the backbone chemistry is similar.
What exactly does US 10,414,831 claim: hydrogenated dextran oligosaccharides and stable ferric oxyhydroxide complexes?
Core invention: A hydrogenated dextran oligosaccharide with a controlled molecular weight distribution and low dimer content, combined with ferric oxyhydroxide to form a stable iron oligosaccharide compound. The stable complex has an “apparent molecular weight” (MP) in a defined range.
Claim structure map (what each claim protects)
- Claim 1: Hydrogenated dextran oligosaccharide as such when combined with ferric oxyhydroxide can form the stable complex. Key point: claim 1 is composition-of-matter for the hydrogenated oligosaccharide defined by distribution/impurity, with functional linkage to forming the iron complex.
- Claims 2–6: The iron oligosaccharide compound (complex) defined by both (i) the hydrogenated dextran distribution/impurity and (ii) MP of the iron complex; plus a sterilization method limitation (autoclaving) in claim 6.
- Claims 7–13: Narrower sub-ranges for hydrogenated dextran MW (including upper limits on Mw and Mn) and tighter “90% by weight” and “10% tail Mw” cutoffs; and lower dimer/monomer content limits.
- Claims 14–16: Additional constraints around Fe content and optional organic hydroxy acid salt (citric acid).
- Claims 17–23: Formulations comprising the iron complex in pharmaceutically acceptable carriers; includes injection liquid and aqueous liquid forms; includes Fe loading ranges.
- Claims 24–30: A second, narrower but distinct “parameter set” for the hydrogenated dextran and resulting iron complex MP band (MP 130,000–160,000 and different MW distribution boundaries).
What are the key claim limitations that define infringement risk in US 10,414,831?
Infringement is likely to turn on meeting all independent claim parameter windows (not just having “dextran-derived iron”). The highest-leverage limitations are:
1) Hydrogenated dextran oligosaccharide MW distribution (percentile-style cutoffs)
Common backbone constraints across claim sets:
- Mw (weight average) between 500 and 3,000 Da (Claim 1 and 2 set) or 500 and 1,600 Da (Claim 24 set).
- Mn (number average) above 500 Da in both sets.
- 90% by weight of hydrogenated dextran have MW < 3,500 Da (Claim 1/2 set) or < 2,700 Da (Claim 24 set).
- 10% by weight tail: Mw of the highest-MW fraction is < 4,500 Da (Claim 1/2 set) or < 3,200 Da (Claim 24 set).
These “distribution-with-tail” limitations are harder to design around casually than single-average specifications.
2) Dimer saccharide content limit (low disaccharide window)
- Claim 1/2 set: dimer content ≤ 2.9 wt%; dependent claims narrow to:
- ≤ 2.5 wt% (Claim 11)
- ≤ 2.3 wt% (Claim 12)
- Claim 24 set: dimer content ≤ 2.3 wt%; dependent claim set also includes monomer ≤ 0.5 wt% (Claim 24 and Claim 30 family logic).
3) Monomer saccharide content (tight impurity control)
- Claim 13: monomer ≤ 0.5 wt% (for claim 2 dependent set).
- Claim 24 set: monomer ≤ 0.5 wt% is explicit in Claim 24.
4) Final iron oligosaccharide “apparent molecular weight” (MP)
This is the second “gate” after the starting dextran distribution.
- Main window: MP between 120,000 and 180,000 Da (Claim 2).
- Narrower windows:
- Claim 3: 130,000–180,000 Da
- Claim 4: 130,000–160,000 Da (tightest common sub-range)
- Alternative parameter set:
- Claim 24: MP 130,000–160,000 Da (explicitly the narrow band)
- (Claim 24 also embeds narrower starting dextran distribution and lower dimer/monomer limits.)
5) Fe content constraint (composition-dependent)
- Claim 14: Fe > 10 wt% and ≤ 50 wt% in the iron oligosaccharide compound.
- Claims 18–21, 29 define formulation iron content as w/v ranges (1–20% w/v and a specific 10% w/v).
6) Optional citrate salt and autoclaving
- Claim 15–16: additional salt of an organic hydroxy acid, specifically citric acid.
- Claim 6: iron oligosaccharide compound sterilized by autoclaving.
Autoclaving and citrate are not required for the core complex claims, but they can expand infringement pathways for specific manufacturing/formulation variants.
Claim-by-claim scope breakdown for US 10,414,831
Independent claims: what do claims 1, 2, 17, and 24 protect?
Claim 1 (hydrogenated dextran oligosaccharide with functional complex-forming capability)
Protected object: hydrogenated oligosaccharide defined by:
- Mw 500–3,000 Da
- Mn > 500 Da
- 90 wt% < 3,500 Da
- 10 wt% tail Mw < 4,500 Da
- dimer content ≤ 2.9 wt%
Functional linkage: when combined with ferric oxyhydroxide, it forms a stable iron oligosaccharide compound.
Key scope implication:
- Claim 1 is not merely a “reportable analysis” claim; the molecular distribution and dimer impurity are structural/process-analytical constraints on the hydrogenated dextran material. Competitors that adjust only tail behavior or dimer content risk exiting the claim even if they can still form an iron complex.
Claim 2 (iron oligosaccharide compound, stable association with ferric oxyhydroxide)
Protected object: the final complex characterized by:
- Hydrogenated dextran MW distribution identical to Claim 1 set (Mw 500–3,000, 90 wt% < 3,500, tail < 4,500, dimer ≤ 2.9, Mn > 500).
- Iron complex MP: 120,000–180,000 Da.
This claim is the main “product-space” gate.
Claim 17 (composition with carrier)
Protected object: composition comprising:
- the iron oligosaccharide compound of Claim 2
- at least one pharmaceutically acceptable carrier
Claim 24 (alternative parameter set with tighter dextran + MP band)
Protected object: iron oligosaccharide compound defined by a stricter dextran distribution and impurity package and a specific MP band:
- Hydrogenated dextran: Mw 500–1,600, Mn > 500
- 90 wt% < 2,700 Da
- tail fraction Mw < 3,200 Da
- dimer ≤ 2.3 wt%
- monomer ≤ 0.5 wt%
- Iron complex MP: 130,000–160,000 Da
Claim 24 is narrower on dextran distribution and impurities but sits on a critical MP window that likely overlaps with many “low-MW dextran-iron” commercial targets.
How do the dependent claims narrow the “parameter space” inside US 10,414,831?
Dextran MW tightening
- Claim 7: hydrogenated dextran Mw ≤ 1,600 Da
- Claim 8: hydrogenated dextran Mn ≤ 1,600 Da
- Claim 9: 90 wt% < 2,700 Da (tighter than Claim 2 baseline)
- Claim 10: tail fraction Mw < 3,200 Da (tighter)
- Claim 25: in claim 24 family, hydrogenated dextran Mw approximately 1,000 Da
Impurity tightening
- Claim 11: dimer ≤ 2.5 wt%
- Claim 12: dimer ≤ 2.3 wt%
- Claim 13: monomer ≤ 0.5 wt%
Iron loading limits
- Claim 14: iron content in the complex > 10 wt% and ≤ 50 wt%
Formulation and administration
- Claim 18–19: injection liquid adapted for human; iron content 1–20% w/v and specifically 10% w/v in Claim 19.
- Claim 20–23: aqueous liquid comprising dissolved/dispersed iron complex.
Manufacturing/process hook
- Claim 6: sterilized by autoclaving.
Citrate salt hook
- Claim 15–16: optional organic hydroxy acid salt; citric acid in Claim 16.
- Claim 27–28: in the Claim 24 family, citrate salt is again available.
What formulations are directly covered: injection liquids, aqueous solutions, iron concentration, citrate?
US 10,414,831 explicitly covers:
- Injection liquid adapted for human (Claims 20–21)
- Aqueous liquid with iron complex dissolved or dispersed (Claims 22–23)
- Iron concentration windows:
- 1–20% w/v (Claim 18 and Claim 29)
- specific 10% w/v (Claim 19)
- Optional citric acid salt (Claims 16 and 28)
If a competitor’s clinical product uses an aqueous injectable iron complex with iron loading inside those bands, the case typically collapses to whether the underlying complex matches the claimed MP and the dextran distribution/impurity constraints.
Where is the claim set most vulnerable to design-around: which parameters are “moving parts”?
The claims use multiple layered specifications. The most practical design-around levers are:
- Tail MW and percentile distribution
- Changing the “90 wt% < X” and “tail Mw of 10% fraction < Y” is a high-impact lever because many competitors may only control average MW.
- Dimer content
- The dimer threshold (≤2.9 wt% baseline; ≤2.3 wt% and ≤2.5 wt% in dependents) is a second high-impact lever. Manufacturing choices in depolymerization/hydrogenation and purification affect this.
- MP of the final complex
- The MP window (120,000–180,000; with key sub-ranges 130,000–160,000) is the third lever. Even if the dextran is within limits, a different complexation state that shifts MP can avoid the claim.
- Exiting the citrate/autoclave variants
- Citrate and autoclaving are not necessary for the core independent complex claims, but they can matter if enforcement focuses on specific manufacturing/formulation lots.
How strong is the patent estate for US 10,414,831-like “iron dextran/oligosaccharide complexes”?
Within the four-corner scope of 10,414,831, strength derives from how it frames the invention:
- It is a chemical/colloidal composition defined by analytical distribution parameters (Mw, Mn, percentile cutoffs) and impurity constraints (dimer, monomer).
- It adds an additional independent “fingerprint,” the complex MP range measured by size exclusion chromatography (Claim 5).
That combination tends to reduce easy equivalency arguments based purely on “similar chemistry,” because the patent is anchored to numerical acceptance windows.
However, enforcement depends on whether accused products generate the same analytical outcomes for:
- hydrogenated dextran MW distribution and dimer/monomer content
- ferric oxyhydroxide association state yielding the same iron complex MP
In practice, these are measurable but fact-intensive, and they can make invalidity and non-infringement analyses hinge on testing methodologies and lot-to-lot variability.
What patent landscape questions does US 10,414,831 raise in US (Orange Book, Paragraph IV, biosimilar) and where do risks concentrate?
Does US 10,414,831 map to an Orange Book listing?
No determination can be made from the provided information alone. The patent could be tied to an approved iron drug product or could be used for licensing around unapproved candidates, but Orange Book status is product-specific.
Paragraph IV (ANDA) and biosimilar relevance
- Paragraph IV: relevant only if the patent is listed in the Orange Book for a reference iron drug product with an ANDA-able generic path.
- Biosimilar: not applicable unless the product is biologic (iron-carbohydrate complexes are generally classified as small-molecule/complex injectables rather than biologics, but the regulatory category must be confirmed for each product).
No status determinations can be made from the provided claim text alone.
When does US 10,414,831 expire and what drives term?
No filing date, priority date, or patent term adjustments can be derived from the provided information. Expiration and terminal disclaimer effects require the patent record.
How does US 10,414,831 compare with typical “iron polymaltose/iron carbohydrate” claim patterns?
Compared with older iron carbohydrate patents that often claim broader composition definitions (e.g., average MW, general dextran/“polymaltose” structures), 10,414,831 is more targeted:
- It uses distribution windows (90 wt%, 10 wt% tail).
- It imposes quantitative carbohydrate impurity limits (dimer, monomer).
- It constrains the final complex MP into a narrow band.
- It includes formulation-specific dependents for injection liquids and iron loading.
This “multi-parameter gate” approach makes it harder to land within the claim by matching only one common feature (like “dextran-derived iron complex”).
Practical competitive assessment: where infringement claims would likely land (commercial product parameters)
Enforcement posture for a patent of this structure typically depends on whether the accused product’s:
- hydrogenated dextran feedstock has the claimed MW distribution and dimer content; and
- resulting iron complex MP lies in 120,000–180,000 (or the tighter 130,000–160,000 band) as measured under the patent’s method assumptions; and
- the accused formulation uses iron concentration and administration form within the dependent claim windows.
If a competitor’s technical package keeps the iron complex in the same MP band and uses hydrogenated dextran with similar tail distribution and low dimer, the claim set becomes a direct licensing and litigation target.
Key Takeaways
- US 10,414,831 is anchored on two tightly coupled specifications: hydrogenated dextran MW distribution/impurity and iron complex MP.
- The most infringement-relevant parameters are the percentile distribution cutoffs (90 wt% and 10 wt% tail MW), dimer/monomer limits, and the iron complex MP band.
- Dependent claims add narrower MW windows, stricter impurity ceilings, Fe loading limits, optional citrate salt, autoclave sterilization, and aqueous injection formulations.
- The claim set’s practical power comes from combining feedstock distribution + complex MP fingerprint, reducing the ability to design around by changing only a single average property.
FAQs
-
What analytical tests are most likely to be disputed for infringement of US 10,414,831?
Testing of hydrogenated dextran MW distribution, dimer/monomer saccharide content, and iron complex MP by size exclusion chromatography.
-
Which claim parameters most strongly affect design-around for competitors?
90 wt% MW cutoff, 10 wt% tail Mw cutoff, dimer saccharide content, and the iron complex MP range.
-
Do citrate salts and autoclaving create separate infringement pathways?
They add dependent-claim coverage, so they can broaden infringement theories for specific lots, but they are not required for the core complex parameters in Claims 2 and 24.
-
How does the presence of a narrow MP band (130,000–160,000 Da) affect licensing leverage?
A narrow MP band compresses the allowable formulation state and increases leverage in disputes where accused products land near but not within the claimed range.
-
Is it sufficient to use “hydrogenated dextran + ferric oxyhydroxide” to infringe US 10,414,831?
No. The claims require specific MW distribution and impurity limits in the hydrogenated dextran plus a defined iron complex MP window, along with the stability association requirement.
References (APA)
No references can be provided from the information supplied in the prompt.
More… ↓
⤷ Start Trial
|
